Navigation Links
Michael J. Fox Foundation awards Mayo Clinic researcher grant to advance Parkinson’s research
Date:3/2/2010

JACKSONVILLE, Fla. For his work contributing to a potential new treatment approach for Parkinson's disease, the Michael J. Fox Foundation (MJFF) for Parkinson's Research has awarded a $500,000 grant to a neuroscientist at the Mayo Clinic campus in Florida.

The researcher, Matthew Farrer, Ph.D., studies how a gene, known as LRRK2, functions normally within brain nerve cells (neurons), and also how it can go awry when mutated. Dr. Farrer was part of the original team who discovered the link between LRRK2 and Parkinson's disease in 2004. A year later, he described LRRK2 G2019S, believed now to be the most common genetic risk factor for Parkinson's disease.

For these reasons, MJFF has identified LRRK2 as a high-priority therapeutic target and has invested nearly $17 million to date for a broad and integrated strategy to drive critical LRRK2-related initiatives at every stage of drug development, according to the foundation. As part of those awards, on Feb. 17, MJFF announced grants of $3.5 million to nine research studies.

Dr. Farrer's work in teasing apart the function of LRRK2 in dictating the structure of neurons earned him the two-year grant. The co-principal investigator on the grant is Justus Daechsel, Ph.D., an assistant professor of Molecular Neuroscience at Mayo Clinic.

"At Mayo, our molecular neuroscience research is now focused on the genetic basis of Parkinson's disease, on the specific proteins and the molecular pathways that are affected," Dr. Farrer says. "Our model and drug development program is designed to halt disease progression, not just to treat the symptoms."

Dr. Farrer and his team have genetically altered mice so that they do not have the LRRK2 gene. When brain cells from these animals are grown in laboratory culture, the researchers have found that neurons without LRKK2 branch out more than do neurons with LRRK2, which shows that the gene normally helps regulate neuronal architecture.

They are using the mice to further understand the function of the protein produced by the LRKK2 gene. "It is a large protein, with many parts. So we are going to replace pieces of the protein, with and without the mutations that predispose people to develop Parkinson's disease, back into cells derived from these animals to see what roles different regions of the protein play," he says. They will also delete other proteins known to interact with the LRRK2 protein to see their effect.

"Answers to these questions are critical for future drug development for patients with Parkinson's disease, and we are pleased the support of the Michael J. Fox Foundation can help us reach our common goal," Dr. Farrer says.


'/>"/>

Contact: Kevin Punsky
punsky.kevin@mayo.edu
904-953-2299
Mayo Clinic
Source:Eurekalert

Related medicine news :

1. Michael J. Fox Foundation Awards $1.1 Million For Clinical Trial of Transdermal Nicotine as Disease-Modifying Treatment For Parkinsons
2. Michael J. Fox Foundation Awards $1 Million to Drive Critical New Research Tools and Technologies in Parkinsons Drug Development
3. Would You Like to Own a Thriller Album Autographed by Michael Jackson Himself?
4. Aton Pharma Announces Michael H. Richardson to Head Orphan Drug Division
5. Michael J. Fox Foundation Awards $2.8 Million to Drive Development of Parkinsons Disease Biomarker Pipeline
6. Aleres Dr. Michael Taitel Presents Compelling Evidence at IBI/NBCH Health & Productivity Forum that Wellness Programs Positively Impact Health & Productivity
7. Michael Jackson Propofol Expert, Barry Friedberg MD, Spoke at Pan Pacific Surgery Meeting
8. TV Wellness Expert Jillian Michaels Teams With Harley-Davidson to Help Women Channel Their Inner Drive and Live More Fulfilling Lives
9. Michael J. Fox Foundation Awards $2 Million for Clinical Research on Postural Instability and Gait Disturbances in Parkinsons Disease
10. Michael J. Fox Foundation Awards $1 Million for Critical Step Toward Development of Dyskinesia Treatments
11. Rush Limbaugh & Michael Steele Join Tea Party Support & Social Security Institute-Demand GOP Senate Stop ObamaCare by Any Means Possible
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2017)... ... July 24, 2017 , ... Horizon Goodwill ... a unique opportunity that helps high school girls succeed in STEM programs as ... Horizon Goodwill will host over 20 high school girls at their corporate ...
(Date:7/24/2017)... OH (PRWEB) , ... July 24, 2017 , ... The ... on the life-altering neurological condition called essential tremor (ET). The seminar will take place ... 5800 Rockside Woods Blvd., Independence, OH. The program will run from 9 a.m. to ...
(Date:7/24/2017)... , ... July 24, 2017 , ... ... media initiatives designed to promote awareness for Topricin’s revolutionary, natural, after-burn skin care ... one of the leading causes of long term skin conditions, including cancer. ...
(Date:7/24/2017)... ... July 24, 2017 , ... Puregraft, the ... announces the issuance of United States Patent Number 9,695,398 (the '398 patent) and ... The '398 and '324 patents cover methods and systems for optimizing fat ...
(Date:7/24/2017)... ... 2017 , ... Sharon Kleyne, host of the nationally syndicated The Sharon Kleyne ... Nature’s Tears® EyeMist® recently talked on the air about an alarming Post magazine article ... by Zidor Aldama described the situation in which Chinese children are under pressure to ...
Breaking Medicine News(10 mins):
(Date:7/13/2017)... Medical Products, a leader in medical product innovation and global patient ... for hospice patient care. ... Centurion Medical Products ... pain management and emotional comfort are part of a hospice,s primary ... preventing unneeded emergency department admission due to severe fecal impaction. One ...
(Date:7/12/2017)... 12, 2017  Eli Lilly and Company (NYSE: ... companies to resolve pending patent litigation in the U.S. District ... regarding the Cialis ® (tadalafil) unit dose patent. ... 2020. As part of the agreement, Cialis exclusivity is now ... "The unit dose patent for Cialis is valid ...
(Date:7/11/2017)... , July 11, 2017  Sysmex America, Inc., ... diagnostic testing equipment as well as middleware information ... way to make quality assurance easier and more ... is well known for the innovation that it ... Monitor elevates quality assurance processes to a new ...
Breaking Medicine Technology: